Last reviewed · How we verify
Tumor necrosis factor alpha
Tumor necrosis factor alpha is a Small molecule drug developed by OncoCareClinic 308 Ltd. It is currently in Phase 2 development. Also known as: TNF-α, Refnot.
Tumor necrosis factor alpha (TNF-alpha) is a chemical messenger produced by the immune system that induces inflammation by binding to its receptors on other cells. It is primarily produced by activated macrophages and has been studied in various clinical trials for conditions such as arthritis, psoriatic arthritis, and periodontal disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tumor necrosis factor alpha |
|---|---|
| Also known as | TNF-α, Refnot |
| Sponsor | OncoCareClinic 308 Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) (PHASE3)
- Pro- and Anti-inflammatory Cytokines in PCOS
- Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tumor necrosis factor alpha CI brief — competitive landscape report
- Tumor necrosis factor alpha updates RSS · CI watch RSS
- OncoCareClinic 308 Ltd portfolio CI
Frequently asked questions about Tumor necrosis factor alpha
What is Tumor necrosis factor alpha?
Who makes Tumor necrosis factor alpha?
Is Tumor necrosis factor alpha also known as anything else?
What development phase is Tumor necrosis factor alpha in?
Related
- Manufacturer: OncoCareClinic 308 Ltd — full pipeline
- Also known as: TNF-α, Refnot
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing